AI Article Synopsis
- Most allogeneic hematopoietic stem cell donations rely on a medication called granulocyte-colony stimulating factor (G-CSF).
- There have been concerns that using G-CSF might lead to the development of blood disorders like myelodysplastic syndromes and acute myelogenous leukemia (MDS/AML).
- Current studies haven't shown a clear increase in these disorders among G-CSF donors, but the existing data isn't strong enough to completely rule out potential long-term risks, so doctors should inform donors about these risks and suggest marrow donation as an alternative.
Article Abstract
A large majority of allogeneic hematopoietic stem cell donations are achieved using granulocyte-colony stimulating factor (G-CSF). G-CSF use has been associated with later development of myelodysplastic syndromes/acute myelogenous leukemia (MDS/AML) in several clinical circumstances. Although clinical data to date have failed to identify any increased incidence of MDS/AML in G-CSF mobilized donors, the quality of these data are insufficient to exclude a long-term risk. Physicians should explain the potential risk to donors, and where appropriate, offer donors the option of marrow donation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bbmt.2011.07.003 | DOI Listing |
Publication Analysis
Top Keywords
hematopoietic stem
8
stem cell
8
g-csf
4
g-csf leukemia
4
leukemia hematopoietic
4
cell donors?
4
donors? large
4
large majority
4
majority allogeneic
4
allogeneic hematopoietic
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!